Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Risk stratification models for smoldering myeloma

Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Mark Bustoros, MD, Weill Cornell Medicine, New York, NY, discusses screening processes to identify patients with smoldering disease at the highest risk of disease progression. Currently, the criteria most commonly used in clinical practice is a model endorsed by the International Myeloma Working Group known as the 20/2/20 criteria. While this risk stratification model can be easily implemented to identify high-risk SMM, it relies solely on clinical biomarkers. Efforts are now focused on including FISH data of translocations and cytogenetics on the risk stratification models. In the future, after proving the efficacy and standardization of such panels, their implementation in clinical care could be of utter significance. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.